ALFA Finder| Metric | Q1 FY27 | Q4 FY26 | Q1 FY26 |
|---|---|---|---|
| Revenue from operations | 6.2 | 6.5 | 5.2 |
| Other income | 0.1 | 0.1 | 0.1 |
| Total income | 6.3 | 6.7 | 5.4 |
| Profit before exceptional items & tax | -0.0 | -0.7 | 0.5 |
| Profit before tax | -0.0 | -0.7 | 0.5 |
| Net profit | -0.0 | -0.7 | 0.5 |
| Operating margin | 0.0% | -10.4% | 9.3% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
| Revenue, year on year | +19.20% |
|---|---|
| Operating profit, year on year | -125.00% |
| Operating profit, quarter on quarter | +87.50% |
BSE results filing, NSE: ASPIRA. Figures extracted from the filing.
Aspira Pathlab & Diagnostics Ltd: key numbers
- Share price
- ₹120.65
- Market cap
- ₹124.2 Cr
- Revenue (annual)
- ₹24.98 Cr
- Net profit (annual)
- ₹0.05 Cr
- P/E (TTM)
- -36.0×Sector 54.5×
- Promoter holding
- 46.65%+0.07% QoQ
- FII holding
- 0.00%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Aspira Pathlab & Diagnostics Ltd
All →Aspira Pathlab & Diagnostics Q2 FY27 Results: Net Loss of ₹1.2 Cr
Aspira Pathlab & Diagnostics Ltd reported revenue from operations of ₹6.3 Cr (-22.2% YoY) and a net loss of ₹1.2 Cr for Q2 FY27.
- Key figure
- Net loss ₹1.2 Cr
Aspira Pathlab & Diagnostics Board Meeting Date
Aspira Pathlab & Diagnostics will hold a board meeting on November 6, 2026 to consider unaudited standalone results for the quarter and half year ended September 30, 2026. The trading window stays closed until 48 hours after the results.
Aspira Pathlab & Diagnostics Other Announcement
Aspira Pathlab & Diagnostics Ltd has filed its quarterly shareholding pattern for the quarter ended September 30, 2026, in compliance with SEBI Listing Regulations.
Aspira Pathlab & Diagnostics Promoter Buying: ₹0.02 Cr
Promoter Jay Arvind Bhanushali acquired 1,424 equity shares of Aspira Pathlab & Diagnostics Ltd via market purchase. The transaction is valued at ₹0.02 Crore.
- Value
- ₹0.02 Cr
- Promoter stake change
- +0.01%
Aspira Pathlab & Diagnostics Promoter Buying
Promoter Jay Arvind Bhanushali acquired 1,424 shares of Aspira Pathlab & Diagnostics Ltd via the open market. This transaction increased the promoter's stake from 7.27% to 7.28%.
- Execution
- 17-09-2026 to 24-09-2026
- Promoter stake change
- +0.01%
Aspira Pathlab & Diagnostics Annual General Meeting
Aspira Pathlab & Diagnostics held its 53rd Annual General Meeting on September 25, 2026, where members deliberated on financial statements and various directorial appointments.